Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Bipolar Depression
NCT03279224Phase 3Unknown
- Start
- Jan 2018
- Primary completion
- Mar 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allogeneic fecal microbiota in bipolar disorder (BD) (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 24 weeks. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03279224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279224.